Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease) and is an indication of a worse prognosis. In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the pulmonary protection was mediated by inhibiting ET-1 (endothelin-1) production. In a double-blind parallel design, 53 COPD patients with PH were randomly assigned to receive either placebo or pravastatin (40 mg/day) over a period of 6 months at a medical centre. Baseline characteristics were similar in both groups. The exercise time remained stable throughout the study in the placebo group. After 6 months, the exercise time significantly increased 52% from 660±352 to 1006±316 s (P<0.0001) in pravastatin-treated patients. With pravastatin, echocardiographically derived systolic PAP (pulmonary artery pressure) decreased significantly from 47±8 to 40±6 mmHg. There was significant improvement in the Borg dyspnoea score after administering pravastatin. Despite unchanged plasma ET-1 levels throughout the study, urinary excretion of the peptide was decreased and significantly correlated with an improvement in exercise time in pravastatin-treated patients (r=−0.47, P=0.01). In conclusion, pravastatin significantly improved exercise tolerance, and decreased PH and dyspnoea during exercise in COPD patients with PH, probably by inhibiting ET-1 synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Sin, D. D., & Man, S. F. P. (2003) · Circulation · doi:10.1161/01.cir.0000056767.69054.b3 · Cited by 1,082
Cited by
Cardiovascular disease and COPD: dangerous liaisons?
Rabe, K. F., Hurst, J. R., & Suissa, S. (2018) · European Respiratory Review · doi:10.1183/16000617.0057-2018 · Cited by 410
Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD
Criner, G. J., Connett, J. E., Aaron, S. D., Albert, R. K., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Curtis, J. L., Dransfield, M. T., Han, M. K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403086 · Cited by 347
Repurposing of statins via inhalation to treat lung inflammatory conditions
Bradbury, P., Traini, D., Ammit, A. J., Young, P. M., & Ong, H. X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.005 · Cited by 38
Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Rysz-Górzynska, M., Gluba-Brzózka, A., Sahebkar, A., Serban, M.-C., Mikhailidis, D. P., Ursoniu, S., Toth, P. P., Bittner, V., Watts, G. F., Lip, G. Y. H., et al. (2016) · Scientific Reports · doi:10.1038/srep30060 · Cited by 33
A systematic review and meta-analysis of trials using statins in pulmonary arterial hypertension
Anand, V., Garg, S., Duval, S., & Thenappan, T. (2016) · Pulmonary Circulation · doi:10.1086/687304 · Cited by 25
Metadata
- Authors
- Lee, T.-M., Chen, C.-C., Shen, H.-N., & Chang, N.-C.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2009-02-12
- Volume
- 116
- Issue
- 6
- Pages
- 497-505
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2044741008
- Cited by
- 104
- References
- 2
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.